| 吉非替尼治疗伴有表皮生长因子受体基因突变的非小细胞肺癌的研究进展 |
| |
| 引用本文： | 李倩琴,李恩泽. 吉非替尼治疗伴有表皮生长因子受体基因突变的非小细胞肺癌的研究进展[J]. 中国临床药理学杂志, 2012, 28(7): 547-549 |
| |
| 作者姓名： | 李倩琴 李恩泽 |
| |
| 作者单位： | 广州南方医院 胸外科,广州,510515 |
| |
| 摘 要： | 肺癌为恶性肿瘤死亡首位原因,而非小细胞肺癌(NSCLC)约占其中的80%。NSCLC中85%以上属中晚期肺癌,5年生存率仅有15%。吉非替尼主要用于晚期非小细胞肺癌(NSCLC)患者经化疗后进展的单用疗法,2003年5月经FDA批准上市。本文对其作用机制、药代动力学进行了概述。
|
| 关 键 词： | 吉非替尼 非小细胞肺癌 表皮生长因子受体 |
Progress in search for gefitinib in the treatment of non - small cell lung cancer with gene mutation of epidermal growth factor receptor |
| |
| LI Qian-qin , LI En-ze. Progress in search for gefitinib in the treatment of non - small cell lung cancer with gene mutation of epidermal growth factor receptor[J]. The Chinese Journal of Clinical Pharmacology, 2012, 28(7): 547-549 |
| |
| Authors: | LI Qian-qin LI En-ze |
| |
| Affiliation: | (Cardiothoracic Vascular Surgery Branch of Nan Fang Hospital,Guangdong 510515,China) |
| |
| Abstract: | Lung cancer is the first death reason for malignant tumors,and non-small cell lung cancer(NSCLC) accounted for about 80% of them.More than 85% of NSCLC lung cancers are in middle-late stage,and the 5 years survival rate is merely about 15%.Gefitinib,which was approved by FDA to come into the market in May 2003,is mainly used for the late non-small cell lung cancer(NSCLC) patients who get progression after chemotherapy.This article involves the mechanism of its action and pharmacokinetics of gefitinib. |
| |
| Keywords: | gefitinib non-small cell lung cancer epidermal growth factor receptor |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
